ALX ONCOLOGY HOLDINGS INC

ALXO

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Redmile Group Driehaus Capital

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Activist Filings

SC 13GRA Capital Management9.9%Feb 9, 2026

Position Details

Redmile GroupNEWFeb 17, 2026

Shares: 3,264,718Value: $3.7M

# Signal Note: Redmile Initiates ALXO Position Redmile's $3.7M entry into ALX Oncology suggests conviction in the company's lead asset ALX148 (CD47 checkpoint inhibitor), which is in Phase 2 development for solid tumors and hematologic malignancies where CD47-mediated immune evasion is a validated resistance mechanism. The timing aligns with anticipated clinical readouts in 2024-2025 that could de-risk the platform and validate the CD47 therapeutic thesis against competitors like Forty Seven Inc (acquired by Gilead) and Arch Oncology. Green's healthcare crossover focus indicates conviction in earlier-stage clinical validation rather than late-stage asset consolidation.

Driehaus CapitalNEW

More ALXO Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

IMNM2 funds XENE2 funds LIVN2 funds SRRK2 funds NGNE2 funds IVVD2 funds PTN1 fund WLDN

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Driehaus Initiates ALXO Position Driehaus Capital's $1.6M entry into ALXO suggests conviction in the company's lead asset, ALX148 (CD47 blockade), which is in Phase 2 development for solid tumors and hematologic malignancies where CD47-mediated immune evasion represents a validated therapeutic target. The timing likely reflects anticipated clinical readouts or data presentations in 2024-2025, as CD47 inhibitors have shown early promise in combination regimens. This is a meaningful signal given Driehaus's established biotech expertise, though position size remains modest relative to fund AUM.